Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.

[1]  Shengtao Xu,et al.  Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain. , 2019, Bioorganic chemistry.

[2]  F. Mollinedo,et al.  Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells. , 2018, European journal of medicinal chemistry.

[3]  Honghao Sun,et al.  Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization. , 2018, ACS medicinal chemistry letters.

[4]  Honghao Sun,et al.  Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities. , 2018, European journal of medicinal chemistry.

[5]  Duane D. Miller,et al.  Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. , 2018, Journal of medicinal chemistry.

[6]  J. Bignon,et al.  A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: Design, synthesis, molecular modelling, and biological evaluation. , 2018, European journal of medicinal chemistry.

[7]  Honghao Sun,et al.  Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. , 2017, Future medicinal chemistry.

[8]  J. Bignon,et al.  Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors. , 2017, European journal of medicinal chemistry.

[9]  Li Huang,et al.  Design, synthesis, and biological evaluation of cyclic-indole derivatives as anti-tumor agents via the inhibition of tubulin polymerization. , 2017, European journal of medicinal chemistry.

[10]  R. Mason,et al.  Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization. , 2016, MedChemComm.

[11]  S. Patil,et al.  Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents, an update (2013-2015). , 2016, Future medicinal chemistry.

[12]  E. Caballero,et al.  Pyridine Based Antitumour Compounds Acting at the Colchicine Site. , 2016, Current medicinal chemistry.

[13]  J. Bignon,et al.  IsoCombretaQuinazolines: Potent Cytotoxic Agents with Antitubulin Activity , 2015, ChemMedChem.

[14]  P. Canonico,et al.  Design, synthesis, and biological evaluation of combretabenzodiazepines: a novel class of anti-tubulin agents. , 2015, Journal of medicinal chemistry.

[15]  S. Ferro,et al.  Targeting GluN2B‐Containing N‐Methyl‐D‐aspartate Receptors: Design, Synthesis, and Binding Affinity Evaluation of Novel 3‐Substituted Indoles , 2014, Archiv der Pharmazie.

[16]  Keduo Qian,et al.  Optimization of 4-(N-Cycloamino)phenylquinazolines as a Novel Class of Tubulin-Polymerization Inhibitors Targeting the Colchicine Site , 2014, Journal of medicinal chemistry.

[17]  Xiao‐Feng Wang,et al.  N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin. , 2013, European journal of medicinal chemistry.

[18]  F. Mollinedo,et al.  Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins. , 2013, Journal of medicinal chemistry.

[19]  Duane D. Miller,et al.  Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents. , 2012, Future medicinal chemistry.

[20]  J. Wdzieczak‐Bakala,et al.  Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: synthesis, cytotoxicity and antitubulin activity. , 2012, European journal of medicinal chemistry.

[21]  J. Bignon,et al.  The Metabolic Fate of isoCombretastatin A‐4 in Human Liver Microsomes: Identification, Synthesis and Biological Evaluation of Metabolites , 2011, ChemMedChem.

[22]  J. Wdzieczak‐Bakala,et al.  Isocombretastatins a versus combretastatins a: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. , 2009, Journal of medicinal chemistry.

[23]  Mark B. Anderson,et al.  Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. , 2009, Journal of medicinal chemistry.

[24]  M. L. Trawick,et al.  Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy. , 2008, Bioorganic & medicinal chemistry.

[25]  V. Pike,et al.  Acetylation of N-Heteroaryl Bromides via PdCl2/(o-tolyl)3P Catalyzed Heck Reactions , 2008 .

[26]  A. McGown,et al.  Differential cytotoxicity of Combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines , 2008, Cancer Chemotherapy and Pharmacology.

[27]  G. Tron,et al.  In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver Microsomes , 2007, Drug Metabolism and Disposition.

[28]  S. Skvortsov,et al.  MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. , 2007, Cancer research.

[29]  B. Trost,et al.  Rhodium-catalyzed cycloisomerization: formation of indoles, benzofurans, and enol lactones. , 2007, Angewandte Chemie.

[30]  Andrea Brancale,et al.  Indole, a core nucleus for potent inhibitors of tubulin polymerization , 2007, Medicinal research reviews.

[31]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[32]  M. Boyd,et al.  Antineoplastic agents. 379. Synthesis of phenstatin phosphate. , 1998, Journal of medicinal chemistry.

[33]  G. Tozer,et al.  Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.

[34]  E. Hamel,et al.  Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. , 1988, Molecular pharmacology.